IBI362 for Chinese adolescents living with obesity or overweight
Tests IBI362 against placebo in adolescents with obesity or overweight.
Plain-language title generated from the registry record
Registry title: A Study of IBI362 in Chinese Adolescents With Obesity or Overweight
Key facts
- Where
- Hangzhou, ChinaSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 12 and 18 years old?
Source: NCT07255209, who can take part
Where in China
- The Children's Hospital, Zhejiang University School of MedicineHangzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Innovent Biologics (Suzhou) Co. Ltd.
- Trial code
- NCT07255209
- Record updated
- 8 January 2026
- Original description
The study is designed to assess the efficacy and safety of multiple doses of IBI362 in Chinese adolescent subjects with obesity or overweight. It plans to enroll 180 adolescents (aged ≥12 and <18 years) who have failed to achieve a 5 kg weight reduction after at least 12 weeks of dietary and exercise intervention.Read full original descriptionShow less
A Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of IBI362 in Chinese Adolescents With Obesity or Overweight（GLORY-YOUNG）
The study is designed to assess the efficacy and safety of multiple doses of IBI362 in Chinese adolescent subjects with obesity or overweight. It plans to enroll 180 adolescents (aged ≥12 and <18 years) who have failed to achieve a 5 kg weight reduction after at least 12 weeks of dietary and exercise intervention.
Inclusion: Participants must meet all of the following inclusion criteria to be enrolled:; Male or female participants aged ≥12 years and <18 years at the time of signing the informed consent/assent form; BMI at screening meeting the obesity criteria defined by "WS/T 586-2018 Screening for Overweight and Obesity in School-Age Children and Adolescents" or meeting overweight criteria plus at least one weight-related comorbidity: prediabetes, type 2 diabetes, hypertension, dyslipidemia, fatty liver disease, or obstructive sleep apnea syndrome; Weight change <5 kg after ≥12 weeks of diet and exercise alone before screening (per self/parental report).
Exclusion: Prior diagnosis of type 1 diabetes; History of (or planned) bariatric surgery (except liposuction/abdominoplasty or acupuncture for weight loss performed >1 year before screening); Pre-pubertal participants (Tanner Stage I).